These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 3315605)

  • 21. Summary of early clinical experience with anisoylated plasminogen streptokinase activator complex in the treatment of acute myocardial infarction.
    Jackson D
    Drugs; 1987; 33 Suppl 3():104-11. PubMed ID: 3315574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of left ventricular function in a randomised study of intravenous anisoylated plasminogen streptokinase activator complex versus heparin in acute myocardial infarction. Preliminary results of the European Multicentre Study (Belgian Centres).
    Taeymans Y; Materne P
    Drugs; 1987; 33 Suppl 3():216-20. PubMed ID: 3315594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Electrocardiographic and enzymatic infarct size in a randomised study of intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
    Hackworthy RA; Sorensen SG; Menlove RL; Anderson JL
    Drugs; 1987; 33 Suppl 3():198-208. PubMed ID: 3315592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anisoylated plasminogen streptokinase activator complex (APSAC). A review of its mechanism of action, clinical pharmacology and therapeutic use in acute myocardial infarction.
    Monk JP; Heel RC
    Drugs; 1987 Jul; 34(1):25-49. PubMed ID: 3308411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose-ranging studies of anisoylated plasminogen streptokinase activator complex. Studies in healthy volunteers and in patients with acute myocardial infarction.
    Marder VJ; Rothbard RL; Fitzpatrick PG; Francis CW; Norry EC
    Drugs; 1987; 33 Suppl 3():124-32. PubMed ID: 3315577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and evaluation of anisoylated plasminogen streptokinase activator complex (APSAC) as a second generation thrombolytic agent.
    Anderson JL
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):22B-27B. PubMed ID: 3312369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and side effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.
    Monassier JP; Hanssen M
    Drugs; 1987; 33 Suppl 3():282-5. PubMed ID: 3315608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acylated streptokinase--plasminogen complex in patients with acute myocardial infarction.
    Walker ID; Davidson JF; Rae AP; Hutton I; Lawrie TD
    Thromb Haemost; 1984 Apr; 51(2):204-6. PubMed ID: 6377564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reperfusion, patency and reocclusion with anistreplase (APSAC) in acute myocardial infarction.
    Anderson JL
    Am J Cardiol; 1989 Jul; 64(2):12A-17A; discussion 24A-26A. PubMed ID: 2662737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid lysis of coronary artery thrombi with anisoylated plasminogen: streptokinase activator complex. Treatment by bolus intravenous injection.
    Marder VJ; Rothbard RL; Fitzpatrick PG; Francis CW
    Ann Intern Med; 1986 Mar; 104(3):304-10. PubMed ID: 3511819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AIMS. The design and conduct of a multicentre mortality study comparing placebo and anisoylated plasminogen streptokinase activator complex 30 units intravenously for the treatment of acute myocardial infarction of less than 6 hours duration. UK APSAC Advisory Committee.
    Drugs; 1987; 33 Suppl 3():227-8. PubMed ID: 3315598
    [No Abstract]   [Full Text] [Related]  

  • 33. Anisoylated plasminogen streptokinase activator complex versus placebo. A preliminary multicentre study of safety and early mortality in acute myocardial infarction.
    Julian DG; Borthwick LS; Reid D; Jennings KP; Wainwright RJ; Rodger JC; Wood D; Phillips WS
    Drugs; 1987; 33 Suppl 3():261-7. PubMed ID: 3315604
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiographic assessment of patency and reocclusion: preliminary results of the Dutch APSAC Reocclusion Multicenter Study (ARMS).
    Visser RF
    Clin Cardiol; 1990 Mar; Suppl 5():V45-7; discussion V67-72. PubMed ID: 2182241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Bolus injection of anisoylated plasminogen-streptokinase activator complex (BRL 26921) as an alternative concept of systemic lysis in acute myocardial infarct].
    Doenecke P; Schwerdt H; Hellstern P; Wenzel E; Bette L
    Klin Wochenschr; 1986 Aug; 64(15):682-7. PubMed ID: 3531704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anisoylated plasminogen streptokinase activator complex in acute myocardial infarction: a placebo-controlled arteriographic coronary recanalization study.
    Timmis AD; Griffin B; Crick JC; Sowton E
    J Am Coll Cardiol; 1987 Jul; 10(1):205-10. PubMed ID: 3298360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multicenter trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: effects on infarct size and left ventricular function.
    Bassand JP; Machecourt J; Cassagnes J; Anguenot T; Lusson R; Borel E; Peycelon P; Wolf E; Ducellier D
    J Am Coll Cardiol; 1989 Apr; 13(5):988-97. PubMed ID: 2647817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A systemic non-lytic state and local thrombolytic failure of anistreplase (anisoylated plasminogen streptokinase activator complex, APSAC) in acute myocardial infarction.
    Brügemann J; van der Meer J; Takens BH; Hillege H; Lie KI
    Br Heart J; 1990 Dec; 64(6):355-8. PubMed ID: 2271340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and tolerance data from the Belgian multicentre study of anisoylated plasminogen streptokinase activator complex versus heparin in acute myocardial infarction.
    Bossaert LL
    Drugs; 1987; 33 Suppl 3():287-92. PubMed ID: 3315610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic effects of BRL 26921 during thrombolytic treatment of acute myocardial infarction.
    Hoffmann JJ; Van Rey FJ; Bonnier JJ
    Thromb Res; 1985 Mar; 37(5):567-72. PubMed ID: 3920779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.